SOMAÍ Oral Solution

SOMAÍ's improved excipient blend offers increased bioavailability through a high concentration of omega-9 fatty acids. Unlike a triglyceride dominate mixture, the Somai excipient blend is predominantly absorbed into the lymphatic system which avoids first-pass metabolism. This increases the potential bioavailability and reduces the amount of Δ9-Tetrahydrocannabinol (THC) being converted to 11-hydroxy-THC (11-OH-THC) by the liver.

SOMAÍ's nanoemulsion blend combines the advantages of the improved excipient with nanoencapsulation to more readily be absorbed into the mucus membranes and stomach lining. This is done by encapsulating the improved excipient blend with a water-soluble shell. Somai's nanoemulsion has a particle size of <200nm and a zeta potential of -30mV to ensure a stable nanoparticle that provides consistent effects dose after dose. Based on the available research Somai's nano emulsified formula will need 7...